
    
      The initial cohort of participants will be enrolled in 3 treatment groups receiving 1) VBR +
      AB-729 + SOC NrtI, 2) VBR + SOC NrtI, or 3) AB-729 + SOC NrtI for up to 48 weeks, each
      followed by an additional 48 weeks of SOC NrtI alone. Up to an additional 2 cohorts may be
      added to the study in future protocol amendments.
    
  